{
    "name": "odevixibat",
    "comment": "Rx",
    "other_names": [
        "Bylvay"
    ],
    "classes": [
        "Ileal Bile Acid Transport Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/bylvay-odevixibat-4000172",
    "pregnancy": {
        "common": [
            "There are no human data on use in pregnant females to establish a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "May cause cardiac malformations in fetus if exposed during pregnancy",
                    "In pregnant rabbits treated orally with odevixibat during organogenesis, an increased incidence of malformations in fetal heart, great blood vessels, and other vascular sites occurred at all doses; maternal systemic exposure at the lowest dose was 2.1x the maximum recommended dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Odevixibat has low absorption following oral administration, and breastfeeding is not expected to result in exposure of infant",
            "No data are available on its presence in human milk, effects on breastfed infants, or effects on milk production",
            "May reduce absorption of FSVs",
            "Monitor FSV levels and increase FSV intake, if FSV deficiency occurs during lactation"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine will decrease the level or effect of odevixibat by  drug binding in GI tract. Modify Therapy/Monitor Closely. Administer bile acid sequestrants 4 hr before or after odevixibat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colesevelam",
            "description": {
                "common": "colesevelam will decrease the level or effect of odevixibat by  drug binding in GI tract. Modify Therapy/Monitor Closely. Administer bile acid sequestrants 4 hr before or after odevixibat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colestipol",
            "description": {
                "common": "colestipol will decrease the level or effect of odevixibat by  drug binding in GI tract. Modify Therapy/Monitor Closely. Administer bile acid sequestrants 4 hr before or after odevixibat."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "21.1-39.1"
        },
        {
            "name": "AST",
            "percent": "12-21.1"
        },
        {
            "name": "ALT increased",
            "percent": "15.8-17.4"
        },
        {
            "name": "Vomiting",
            "percent": "13-15.8"
        },
        {
            "name": "Abdominal pain",
            "percent": "7.1-15.8"
        },
        {
            "name": "FSV deficiency",
            "percent": "10.5-13"
        },
        {
            "name": "Blood bilirubin increased",
            "percent": "4.8-10.5"
        },
        {
            "name": "Splenomegaly",
            "percent": "2.4-5.3"
        },
        {
            "name": "Cholelithiasis",
            "percent": "2.4-5.3"
        },
        {
            "name": "Dehydration",
            "percent": "4.3"
        },
        {
            "name": "Fracture",
            "percent": null
        }
    ]
}